Skip to main content

Table 2 Comparison between 78 critically ill patients with SARS-CoV-2 pneumonia developing (n = 26) or not (n = 52) eosinophilia (eosinophils count > 500mm3) during ICU stay

From: Eosinophilia in critically ill COVID-19 patients: a French monocenter retrospective study

  All patients N = 78 Patients with eosinophilia N = 26 Patients without eosinophilia N = 52 p
Patients characteristics and ICU scores
 Male sex 62 (79) 22 (85) 40 (77) 0.62
 Age, years 62 [54–70] 62 [55–70] 62 [54–70] 0.84
 SOFA 4 [3–7] 4 [3–7] 4 [3–8] 0.44
 SAPS II 33 [22–44] 34 [28–38] 31 [19–44] 0.72
 Days between disease onset and ICU admission 8 [7–12] 10 [7–13] 8 [7–12] 0.28
Main comorbidities, n (%)
 Obesity (body mass index ≥ 30 kg/m2) 36 (46) 9 (36) 27 (53) 0.25
 Arterial hypertension 51 (65) 13 (50) 38 (73) 0.08
 Diabetes mellitus 33 (42) 12 (46) 21 (40) 0.81
 Ischemic cardiopathy 8 (10) 3 (12) 5 (10) 1.00
 Cerebro-vascular diseases 7 (9) 4 (15) 3 (6) 0.21
 Venous thrombo-embolism 5 (6) 2 (8) 3 (6) 1.00
 Chronic respiratory diseases 18 (23) 6 (24) 12 (24) 1.00
 Chronic renal failure 7 (9) 2 (8) 5 (10) 1.00
 Recent cancer or hemopathy 3 (4) 1 (4) 2 (4) 1.00
 ACE or ARB 35 (45) 11 (42) 24 (47) 0.88
Biological data at ICU admission
 Median eosinophils count (cell/mm3) 0 [0–10] 5 [0–20] 0 [0–10] 0.43
 Eosinophilia (> 500/mm3) 1 (1) 1 (4) 0 (0) 0.33
 Eosinopenia (< 40/mm3) 69 (88) 22 (85) 47 (90) 0.47
 No eosinophils 47 (60) 13 (50) 34 (65) 0.29
 Fibrinogen (g/L) 8 [6–9] 7 [6–8] 8 [7–9] 0.37
 D-dimers (µg/mL) 2440 [1570–9915] 2415 [1968–13670] 2720 [1400–7250] 0.36
 Prothrombin time (%) 85 [75–96] 87 [80–96] 85 [70–96] 0.59
 Platelets count (G/L) 225 [164–291] 209 [190–327] 226 [161–272] 0.34
Treatment for SARSCoV-2 pneumonia
 Glucocorticoidsa 12 (15) 4 (15) 8 (15) 1.00
 Hydroxychloroquineb 2 (3) 1 (4) 1 (2) 1.00
 Azithromycin 0
 Remdesivir 0
 Lopinavir–ritonavir 0
 Tocilizumab 0
Outcomes in the ICU
 Invasive mechanical ventilation 68 (87) 25 (96) 43 (83) 0.15
 Prone positioning 48 (62) 18 (69) 30 (58) 0.46
 Vasopressor support 49 (63) 19 (73) 30 (58) 0.28
 Acute kidney failure 55 (71) 19 (79) 36 (69) 0.53
 Renal replacement therapy 24 (31) 12 (46) 12 (23) 0.07
 Ventilator-associated pneumonia 45 (58) 19 (73) 26 (50) 0.09
 Thrombotic event during ICU stay 33 (42) 12 (48) 21 (40) 0.70
 Length of ICU stay, days 16 [8–30] 31 [23–52] 12 [6–21]  < 0.001
 ICU mortality 38 (49) 9 (35) 29 (56) 0.13
 Days between ICU admission and death 13 (8–21) 23 (18–47) 12 (8–16)  < 0.001
  1. Continuous variables are reported as median [Interquartile range] and compared between groups using the Student t test. Categorical variables are reported as numbers and percentages and compared using χ2 test. A p value < 0.05 was considered significant
  2. ACE/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ICU intensive care unit, SAPS2 simplified acute physiology score, SOFA sepsis-related organ failure assessment
  3. aIn a context of randomized clinical trial (n = 10) or as a salvage therapy (n = 2)
  4. bIn a context of randomized clinical trial